Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Susan M Domchek

Showing results (261-270 of 361) with videos related to

Pageof 37
Sort By:
NPJ Breast Cancer|June 27, 2017
A functionally significant SNP in TP53 and breast cancer risk in African-American womenMaureen E Murphy, Song Liu, Song Yao, et al.
Journal of Medical Genetics|August 15, 2012
BRCA1 R1699Q variant displaying ambiguous functional abrogation confers intermediate breast and ovarian cancer riskAmanda B Spurdle, Phillip J Whiley, Bryony Thompson, et al.
Biorxiv : the Preprint Server for Biology|September 10, 2024
Tumor suppressor heterozygosity and homologous recombination deficiency mediate resistance to front-line therapy in breast cancerAnton Safonov, Antonio Marra, Chaitanya Bandlamudi, et al.
NPJ Breast Cancer|September 23, 2020
Association of germline variation with the survival of women with <i>BRCA1/2</i> pathogenic variants and breast cancerTaru A Muranen, Sofia Khan, Rainer Fagerholm, et al.
Cancer Research|July 18, 2020
A Rare <i>TP53</i> Mutation Predominant in Ashkenazi Jews Confers Risk of Multiple CancersJacquelyn Powers, Emilia M Pinto, Thibaut Barnoud, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 9, 2023
Contralateral Breast Cancer Risk Among Carriers of Germline Pathogenic Variants in <i>ATM</i>, <i>BRCA1</i>, <i>BRCA2</i>, <i>CHEK2</i>, and <i>PALB2</i>Siddhartha Yadav, Nicholas J Boddicker, Jie Na, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|February 11, 2026
NCCN Guidelines® Insights: Genetic/Familial High-Risk Assessment: Breast, Ovarian, Pancreatic, and Prostate, Version 2.2026Heather H Cheng, Veda N Giri, Michael Goggins, et al.
Cancer Research|July 30, 2011
Modification of BRCA1-Associated Breast and Ovarian Cancer Risk by BRCA1-Interacting GenesTimothy R Rebbeck, Nandita Mitra, Susan M Domchek, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|October 19, 2023
NCCN Guidelines® Insights: Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic, Version 2.2024Mary B Daly, Tuya Pal, Kara N Maxwell, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 21, 2021
Germline Pathogenic Variants in Cancer Predisposition Genes Among Women With Invasive Lobular Carcinoma of the BreastSiddhartha Yadav, Chunling Hu, Katherine L Nathanson, et al.
Pageof 37

Showing results (261-270 of 361) with videos related to

Sort By:
Pageof 37
NPJ Breast Cancer|June 27, 2017
A functionally significant SNP in TP53 and breast cancer risk in African-American womenMaureen E Murphy, Song Liu, Song Yao, et al.
Journal of Medical Genetics|August 15, 2012
BRCA1 R1699Q variant displaying ambiguous functional abrogation confers intermediate breast and ovarian cancer riskAmanda B Spurdle, Phillip J Whiley, Bryony Thompson, et al.
Biorxiv : the Preprint Server for Biology|September 10, 2024
Tumor suppressor heterozygosity and homologous recombination deficiency mediate resistance to front-line therapy in breast cancerAnton Safonov, Antonio Marra, Chaitanya Bandlamudi, et al.
NPJ Breast Cancer|September 23, 2020
Association of germline variation with the survival of women with <i>BRCA1/2</i> pathogenic variants and breast cancerTaru A Muranen, Sofia Khan, Rainer Fagerholm, et al.
Cancer Research|July 18, 2020
A Rare <i>TP53</i> Mutation Predominant in Ashkenazi Jews Confers Risk of Multiple CancersJacquelyn Powers, Emilia M Pinto, Thibaut Barnoud, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 9, 2023
Contralateral Breast Cancer Risk Among Carriers of Germline Pathogenic Variants in <i>ATM</i>, <i>BRCA1</i>, <i>BRCA2</i>, <i>CHEK2</i>, and <i>PALB2</i>Siddhartha Yadav, Nicholas J Boddicker, Jie Na, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|February 11, 2026
NCCN Guidelines® Insights: Genetic/Familial High-Risk Assessment: Breast, Ovarian, Pancreatic, and Prostate, Version 2.2026Heather H Cheng, Veda N Giri, Michael Goggins, et al.
Cancer Research|July 30, 2011
Modification of BRCA1-Associated Breast and Ovarian Cancer Risk by BRCA1-Interacting GenesTimothy R Rebbeck, Nandita Mitra, Susan M Domchek, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|October 19, 2023
NCCN Guidelines® Insights: Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic, Version 2.2024Mary B Daly, Tuya Pal, Kara N Maxwell, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 21, 2021
Germline Pathogenic Variants in Cancer Predisposition Genes Among Women With Invasive Lobular Carcinoma of the BreastSiddhartha Yadav, Chunling Hu, Katherine L Nathanson, et al.
Pageof 37